AgeneBio, Inc., is an emerging pharmaceutical company developing innovative therapeutics that are structured around preventing neurodegeneration and preserving and restoring cognitive function for previously unserved patients battling amnestic mild cognitive impairment (aMCI) -- the symptomatic pre-dementia stage of Alzheimerâs disease, and other neurological and psychiatric diseases. AgeneBioâs novel pipeline of therapies is anchored in decades of research at Johns Hopkins University and leading research centers worldwide. Thsi work has shown that overactivity in the hippocampus contributes to cognitive impairment and drives neurodegeneration if not controlled. This overactivity is a characteristic feature of aMCI. If approved, AgeneBioâs Phase 3-ready lead candidate, AGB101, would be the first (and only therapeutic targeting hippocampal overactivity and potentially the first therapeutic to slow progression to, and delay the onset of, Alzheimerâs dementia. AgeneBio also has a novel GABA-A alpha5 small molecule program in late discovery stage with therapeutic potential for a spectrum of untreated conditions including aMCI, autism and schizo
